IMGN Marches Forward, FDA Nod For ZLTQ, Knight Lends Shine To PLX

Canada-based Knight Therapeutics Inc. (GUD.TO) has acquired 6.3 million common shares of Protalix BioTherapeutics Inc. (PLX) at an average price of US$0.57 per share.

from RTT - Biotech http://ift.tt/2jar0zj
via IFTTT